(19)
(11) EP 3 156 494 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.09.2018 Bulletin 2018/38

(45) Mention of the grant of the patent:
25.04.2018 Bulletin 2018/17

(21) Application number: 16200237.2

(22) Date of filing: 03.12.2009
(51) International Patent Classification (IPC): 
C12N 15/85(2006.01)

(54)

GENOME EDITING IN RATS USING ZINC-FINGER NUCLEASES

GENOMÄNDERUNG BEI RATTEN MITHILFE VON ZINK-FINGER-NUKLEASEN

ÉDITION DE GÉNOME CHEZ DES RATS AU MOYEN DE NUCLÉASES EN DOIGT DE ZINC

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 04.12.2008 US 200985 P
26.01.2009 US 205970 P
24.11.2009 US 263904 P

(43) Date of publication of application:
19.04.2017 Bulletin 2017/16

(62) Application number of the earlier application in accordance with Art. 76 EPC:
09830727.5 / 2352369

(73) Proprietors:
  • Sangamo Therapeutics, Inc.
    Richmond, CA 94804 (US)
  • Sigma-Aldrich Co.
    St. Louis, MO 63103 (US)

(72) Inventors:
  • CUI, Xiaoxia
    St. Louis, MO 63146 (US)
  • GEURTS, Aron M.
    New Berlin, WI 53151 (US)
  • URNOV, Fyodor
    Richmond, CA 94804 (US)

(74) Representative: Weickmann & Weickmann PartmbB 
Postfach 860 820
81635 München
81635 München (DE)


(56) References cited: : 
EP-A1- 1 348 335
WO-A2-03/080809
US-A1- 2009 205 083
 WO-A1-2008/151081
WO-A2-03/087341
   
  • MILLER JEFFREY C ET AL: "An improved zinc-finger nuclease architecture for highly specific genome editing", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 7, 1 July 2007 (2007-07-01), pages 778-785, XP002465119, ISSN: 1087-0156, DOI: 10.1038/NBT1319
  • URNOV F D ET AL: "Highly efficient endogenous human gene correction using designed zinc-finger nucleases", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 435, no. 7042, 2 June 2005 (2005-06-02), pages 646-651, XP002411069, ISSN: 0028-0836, DOI: 10.1038/NATURE03556
  • PORTEUS M H ET AL: "GENE TARGETING USING ZINC FINGER NUCLEASES", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 8, 1 August 2005 (2005-08-01) , pages 967-973, XP002467422, ISSN: 1087-0156, DOI: 10.1038/NBT1125
  • DOYON Y ET AL: "Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases", NATURE BIOTECHNOLOGY, GALE GROUP INC, US, vol. 26, no. 6, 1 June 2008 (2008-06-01), pages 702-708, XP002512110, ISSN: 1087-0156, DOI: 10.1038/NBT1409 [retrieved on 2008-05-25]
  • MENG XIANGDONG ET AL: "Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases", NATURE BIOTECHNOLOGY, GALE GROUP INC, US, vol. 26, no. 6, 1 June 2008 (2008-06-01), pages 695-701, XP002512111, ISSN: 1087-0156, DOI: 10.1038/NBT1398 [retrieved on 2008-05-25]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).